Last reviewed · How we verify
NCT06381258
Fetal Cardiac Function
trial testing Ultrasound in Fetal Growth Retardation in 72 participants. Completed in 12 December 2024.
1 December 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 30 April 2024 |
| Primary completion | 1 December 2024 |
| Estimated completion | 12 December 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Ultrasound
Conditions studied
- Fetal Growth Retardation — all drugs for Fetal Growth Retardation →
Sponsor
Assiut University
Who can join
Eligibility, female only, with Fetal Growth Retardation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study is to evaluate the effect of PE and FGR on fetal cardiac function. Pregnancies with preeclampsia and FGR, and preeclampsia with normal fetal growth are evaluated by echocardiography and compared with uncomplicated pregnancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06381258
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ultrasound
Trials testing the same drug.
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07505433 — Ultrasound Monitoring of Bone Healing in Ilizarov Bone Transport · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
- NCT07342790 — Artificial Intelligence Clinical Decision · NA · not yet recruiting
- NCT07169890 — Clinical Insights Into Dextrose Phonophoresis on Mild to Moderate Acne Vulgaris · NA · completed
Other recruiting trials for Fetal Growth Retardation
Currently open trials in the same condition.
- NCT06952777 — Validation of Sensors for Long-term Non-Invasive Fetal Monitoring · NA · recruiting
- NCT06405360 — DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development · NA · active not recruiting
- NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
- NCT06215690 — Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction · active not recruiting
- NCT06416995 — Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06381258 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06381258.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing